Cell Therapy Clinical Trials

2 recruiting

Frequently Asked Questions

Common questions about Cell Therapy clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 19 of 9 trials

Recruiting
Phase 2

DALY II Japan/MB-CART2019.1 for DLBCL

DLBCL - Diffuse Large B Cell LymphomaCAR-T Cell Therapy
Miltenyi Biomedicine GmbH31 enrolled5 locationsNCT07288879
Recruiting
Early Phase 1

TC-D101 Cell Therapy for Patients With DLL3-Positive SCLC

Small Cell Lung Cancer ( SCLC )CAR-T Cell Therapy
TCRCure Biopharma Ltd.24 enrolled1 locationNCT07246304
Recruiting
Phase 1

A Study of A-CAR028 Treatment in Subjects With Relapsed or Refractory Acute Myeloid Leukemia

CAR-T Cell TherapyAcute Myeloid Leukemia (AML)
First Affiliated Hospital of Zhejiang University20 enrolled1 locationNCT07198867
Recruiting
Phase 1Phase 2

MSC Exosome Therapy for Post-Preeclampsia Endothelial Dysfunction

PostpartumPreeclampsiaCell Therapy+2 more
Universitas Padjadjaran80 enrolled1 locationNCT07183384
Recruiting

CytOSorb TreatMent Of Critically Ill PatientS Registry

SepsisLiver Transplant; ComplicationsPancreatitis+15 more
CytoSorbents, Inc3,000 enrolled28 locationsNCT05146336
Recruiting
Early Phase 1

Exercise as an Immune Adjuvant for Allogeneic Cell Therapies

LymphomaLeukemiaCAR-T Cell Therapy+3 more
University of Arizona100 enrolled1 locationNCT06643221
Recruiting
Not Applicable

Early Integration of Palliative and Supportive Care in Cellular Therapy

Multiple MyelomaLymphomaLeukemia+3 more
Alberta Health Services, Calgary152 enrolled1 locationNCT05190653
Recruiting
Phase 1

Mesothelin/GPC3/GUCY2C-CAR-T Cells Against Cancers

Pancreas CancerSolid Tumor, AdultCAR-T Cell Therapy+1 more
Second Affiliated Hospital of Guangzhou Medical University30 enrolled1 locationNCT05779917
Recruiting
Phase 1

GPC3/Mesothelin-CAR-γδT Cells Against Cancers

Liver CancerLung CancerPancreas Cancer+3 more
Second Affiliated Hospital of Guangzhou Medical University30 enrolled1 locationNCT06196294